Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9221110 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL11892683 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12763881 | 0.89 | MEN1 (0.57) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10035 | 0.88 | NPC1 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23795562 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL24943484 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL24943483 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL10290153 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL26302645 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 | |
| SCHEMBL23795581 | 0.86 | GNAI3 (0.62) | MEN1POLBMAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| EP-0666879-A1 | METHOD OF PREPARING STABILIZED AROMATIC DIAMINES, AND THEIR USE IN THE PRODUCTION OF HEAT-RESISTANT POLYURETHANE/UREA ELASTOMERS | BAYER AG (DE) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995003421-A1 | PROCESS FOR THE ENZYMATIC PREPARATION OF OPTICALLY ACTIVE N-SUBSTITUTED-3-PYRROLIDINOL | DSM N.V. (NL) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994010219-A1 | METHOD OF PREPARING STABILIZED AROMATIC DIAMINES, AND THEIR USE IN THE PRODUCTION OF HEAT-RESISTANT POLYURETHANE/UREA ELASTOMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | CHRNB2 21/4885CHRNA3 7/4885CHRNA4 5/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CHRNB2 1645/4885CHRNA3 1802/4885CHRNA4 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.